The analysis utilized a Cox proportional hazard model to account and adjust for variables which may have differed between treatment populations, such as age, cost of index procedure, comorbidities, adverse events, and site of service. The research defines differences between return procedures (post-operative procedure performed during a return visit to an outpatient setting identified by a CPT or ICD 9/10 code), and surgical retreatment occurring after the original index.
The database included 5,228 UroLift System prostatic urethral lift (PUL) patients 19,507 transurethral resection of the prostate (TURP) patients 10,173 GreenLight patients and 935 Rezūm ** patients. Medicare and commercial claims from IBM Watson among men with a BPH diagnosis who received therapy for the condition in an outpatient setting from 2015 through 2019. The study analyzed a representative sample of U.S. “This study revealed real-world surgical retreatment rates that are comparable among the UroLift System, TURP and GreenLight while highest for Rezūm.” Until now, comprehensive healthcare utilization data that includes surgical retreatment rates have been missing from the urologist toolbox when discussing these important factors surrounding treatment options with their BPH patients,” said Dr. “It is important for urologists to have access to well-designed, large-scale, real-world comparative data for surgical and minimally invasive BPH treatments. Medicare and Commercial Claims,” which was sponsored by Teleflex, was presented Sunday, September 12 by Steven Kaplan +, M.D., of Mount Sinai, New York City, at the virtual American Urological Association (AUA) 2021 Annual Meeting. The study “UroLift PUL Compared to Rezūm, TURP and GreenLight PVP: Results From an Analysis of U.S. The data also show that the risk of surgical retreatment is similar between UroLift PUL, TURP and GreenLight™ PVP while highest following Rezūm™ Water Vapor Therapy. 14, 2021 (GLOBE NEWSWIRE) - Teleflex Incorporated (NYSE:TFX) today announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift ® System among the analyzed benign prostatic hyperplasia (BPH) treatment options. No interpretable trends in DVT counts were discovered.Ĭonclusions: Appropriate use of MCs and USGPIVs by an IR-supported VAT significantly decreased PICCs and MCs, respectively.WAYNE, Pa., Sept. CLABSI rates per 1000 central venous catheter days decreased from 1.5 to 0.44 ( P < 0.01), coinciding with an unrelated CLABSI reduction initiative.
GUIDELINER ICD 10 CODE TELEFLEX FULL
Following full implementation of USGPIV in January 2016, MCs decreased 34% from 2015 to 2016 ( P < 0.01) with no concurrent decrease in PICCs ( P = 0.72).
From the peak of PICC placements in 2006 to the peak of MCs in 2010, PICCs decreased 23% ( P < 0.01), while MCs increased 93% ( P < 0.001). Results: The VAT documented 33,113 PICC, 12,135 MC, and 14,300 USGPIV placements from September 2001 to March 2018.
Analysis of hospital records of upper extremity DVT and CLABSI was also performed.
Materials: A retrospective analysis of PICCs, MCs, and USGPIVs placed in inpatients in a large tertiary care academic hospital was conducted, using the VAT’s record supplemented with data from the IR quality assurance database. This report evaluates this effort to reduce PICCs and MCs through appropriate patient-centered device choice. Because of these risks, midline catheters (MCs) and ultrasound-guided peripheral intravenous catheters (USGPIVs) were added to the capabilities of the host institution’s nursing-based venous access team (VAT), which operates under the direction of Interventional Radiology (IR). Purpose: Deep vein thrombosis (DVT) and central line-associated bloodstream infection (CLABSI) are serious complications of peripherally inserted central catheters (PICCs).
0 kommentar(er)
